Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly

Fanelli, Giuseppe; Benedetti, Francesco; Wang, Sheng Min; Lee, Soo Jung; Jun, Tae-Won; Masand, Prakash S.; Patkar, Ashwin A.; Han, Changsu; Serretti, Alessandro; Pae, Chi Un; Fabbri, Chiara

doi:10.1007/s00406-019-01090-1

Cited by 9 publications

(7 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 Furthermore, our findings were also consistent with earlier studies showed decreased levels of Fetuin-A in Alzheimer's disease (ALD), major depressive disorder (MDD). 8,16 Though caution should be applied in the interpretation of our rdata, suggesting a possible role for Fetuin-A in ASD.…”

Section: Discussionmentioning

confidence: 97%

“…Recently Fanelli et al suggested lower Fetuin-A level as potential biomarker of depression in elderly people. 16 …”

Section: Introductionmentioning

confidence: 99%

“…Recently Fanelli et al suggested lower Fetuin-A level as potential biomarker of depression in elderly people. 16 Oxidative stress plays a key role in the pathogenesis of several chronic and acute neurological disorders including ASD. 17 Kanno et al 18 proposed that Fetuin-A is strongly associated to the cytoprotective activity against oxidative injury in neuronal cells in vitro.…”

mentioning

confidence: 99%

See 2 more Smart Citations

The possible link between Fetuin-A Protein and Neuro-inflammation in Children with Autism Spectrum Disorder

Al-Ayadhi¹,

Alghamdi²,

Altamimi³

et al. 2021

Pak J Med Sci

View full text Add to dashboard Cite

Objectives: To investigate the blood plasma levels of Fetuin-A protein in children with Autism Spectrum Disorder (ASD) and healthy controls that could offer novel diagnostic biomarkers of disease development in ASD. Another objective was to investigate the severity of autistic children by Childhood Autism Rating Scale (CARS) and Short Sensory Profile (SSP). Methods: This case control study was carried out at Autism Research and Treatment (ART) Center, King Saud University, Riyadh, Saudi Arabia, from October 2019 to February 2020. Plasma concentration of Fetuin-A was analyzed by enzyme-linked immunosorbent assay (ELISA) in ASD subjects (n=46) and normal controls (n=44). Correlation among Fetuin-A levels, CARS and SSP was established by Spearman’s correlation coefficient (r). Results: Overall, autistic children had significantly (p= 0.0.02) lower Fetuin-A concentration [50.76 (22.2-68.5) ng/ml] than those of healthy controls [53.7 (35.6-99.7) ng/ml] [median (interquartile range)]. Children with mild to moderate autism (n=24, 52%) also showed significantly lower Fetuin-A levels [50.0 (30.0-68.2) ng/ml], (p =0.02} than healthy controls [53.7 (35.6-99.7) ng/ml] [median (IQR)]. However, there was no significant change (p = 0.71) observed between the Fetuin-A levels of children with severe autism [51.8 (22.2-68.5)] ng/ml, mild to moderate autism [50 (30-68.2)] ng/ml [median (IQR)] and healthy controls (p=0.12). Also no significant correlations between Fetuin-A, CARS and SSP were observed (CARS, r= 0.024, p=0.88; SSP, r= -0.003, p=0.98). Conclusion: Overall the low Fetuin-A plasma values in ASD subjects, most likely show that Fetuin-A could be associated in the physiology of autism. Further studies with larger patient and control cohorts will be necessary to determine whether Fetuin-A can be used as a biomarker for ASD. doi: https://doi.org/10.12669/pjms.37.4.4032 How to cite this:Al-Ayadhi LY, Alghamdi FA, Altamimi LA, Alsughayer LY, Alhowikan AM, Halepoto DM. The possible link between Fetuin-A Protein and Neuro-inflammation in Children with Autism Spectrum Disorder. Pak J Med Sci. 2021;37(4):---------. doi: https://doi.org/10.12669/pjms.37.4.4032 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Discussionmentioning

confidence: 97%

“…Recently Fanelli et al suggested lower Fetuin-A level as potential biomarker of depression in elderly people. 16 …”

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

The possible link between Fetuin-A Protein and Neuro-inflammation in Children with Autism Spectrum Disorder

Al-Ayadhi¹,

Alghamdi²,

Altamimi³

et al. 2021

Pak J Med Sci

View full text Add to dashboard Cite

show abstract

“…The hypoalbuminemia may be associated with reduced tryptophan availability, reduced serum Zinc levels or maladjusted antioxidant defenses in MDD [24]. Reduced plasma alpha‐2‐HS‐glycoprotein may be related to impaired anti‐inflammatory activity and microglia dysregulation, a promising biomarker of MDD in the elderly [25]. Increased plasma immunoglobulins may be involved in severe oxidative stress in MDD [26].…”

Section: Discussionmentioning

confidence: 99%

Plasma nontargeted peptidomics discovers potential biomarkers for major depressive disorder

Wang

Liu

Liú

et al. 2021

Proteomics Clinical Apps

View full text Add to dashboard Cite

Purpose There are great demands for identifying biomarkers of major depressive disorder (MDD), a common mental illness with a prevalence of approximately 6%. Finding potential biomarkers to aid MDD diagnosis is in high demand. Experimental Design In this study, a combination of pretreatment methods named salt‐out assisted liquid‐liquid extraction (SALLE) and nontargeted peptidomics based on nano‐LC‐Orbitrap/MS was primarily employed to discover the candidate peptide markers from the plasma of 238 subjects. Results Many peptides were enriched and identified from the plasma, 42 of which showed significant differences between MDD patients and controls by univariate statistical analysis. A binary logistic regression (BLR) model combined four peptide markers (P1, P9, P17, P29) was established, yielding an overall prediction accuracy of 91.7% and 82.2% in the discovery and validation sets, respectively. Conclusions and Clinical Relevance In conclusion, the excellent performance of the BLR model in both discovery and validation sets demonstrates the robustness of the four peptide markers panel. It is very valuable for quantification of the absolute content of four peptides and further verification.

show abstract

“…It may be argued that DNA variants do not capture completely the complex biology of depression, therefore transcriptomic biomarkers have also been extensively investigated, by our group and others [ 29 - 31 ]. Many results were reported, also focusing on specific clinical aspects such as suicidal behaviors, but unequivocal confirmation is still lacking [ 32 - 34 ].…”

Section: Biomarkers In Major Depressive Disordersmentioning

confidence: 99%

Clinical Utility of Fluid Biomarker in Depressive Disorder

Serretti

2022

Clin Psychopharmacol Neurosci

Self Cite

View full text Add to dashboard Cite

Major depressive disorders are ranked as the single largest contributor to non-fatal health loss and biomarkers could largely improve our routine clinical activity by predicting disease course and guiding treatment. However there is still a dearth of valid biomarkers in the field of psychiatry. The initial assumption that a single biomarker can capture the myriad of complex processes proved to be naive. The purpose of this paper is to critically review the field and to illustrate the possible practical application for routine clinical care. Biomarkers derived from DNA analysis are the ones that have received the most attention. Other potential candidates include circulating transcription products, proteins, and inflammatory markers. DNA polygenic risk scores proved to be useful in other fields of medicine and preliminary results suggest that they could be useful both as risk and diagnostic biomarkers also in depression and for the choice of treatment. A number of other possible fluid biomarkers are currently under investigation for diagnosis, outcome prediction, staging, and stratification of interventions, however research is still needed before they can be used for routine clinical care. When available, clinicians may be able to receive a lab report with detailed information about disease risk, outcome prediction, and specific indications about preferred treatments.

show abstract

Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly

Cited by 9 publications

References 90 publications

The possible link between Fetuin-A Protein and Neuro-inflammation in Children with Autism Spectrum Disorder

The possible link between Fetuin-A Protein and Neuro-inflammation in Children with Autism Spectrum Disorder

Plasma nontargeted peptidomics discovers potential biomarkers for major depressive disorder

Clinical Utility of Fluid Biomarker in Depressive Disorder

Contact Info

Product

Resources

About